Personalized Biomarker-Guided Treatment for Women with Endometrial and Ovarian Cancer Using Hormone Receptors and Stathmin Levels

What this Trial Is About

Researchers are evaluating the use of specific molecular biomarkers to personalize treatment for patients with endometrial cancer. This study focuses mainly on biomarkers found promising in previous research and aims to improve surgical and medical treatment decisions. The trial has two parts one tests the use of biomarkers to guide lymphadenectomy during surgery, and the other assesses the biomarker stathmins potential to predict response to taxane chemotherapy in endometrial and ovarian cancer. The study includes an implementation phase where lymphadenectomy is performed based on hormone receptor status ER and PR to define patient risk and guide surgery. Patients considered low risk based on tumor grade and receptor status may avoid lymphadenectomy, while higher-risk patients undergo pelvic and para-aortic lymphadenectomy. In the second phase, patients receiving weekly taxane treatment have tissue biopsies and urine samples analyzed for stathmin levels before and during treatment. Imaging scans and blood tests are conducted regularly to monitor disease progression. Participants will receive routine clinical follow-up for five years, including quality of life questionnaires. Researchers will collect data on survival, disease recurrence, and quality of life over this period. For patients in the taxane treatment phase, urine and blood samples will be collected weekly, with imaging every eight treatment cycles. The studys main outcomes include the number of cancer recurrences after five years and the duration of treatment response in metastatic disease, along with correlations of stathmin levels in various samples.

Biomarker Guided Treatment in Gynaecological Cancer